By Christian Cobaugh, CEO and Founder Monoclonal antibodies (mAbs) have emerged as one of the most successful drug products and biochemical reagents of the 21st century, owing to their broad range of activities, target specificity, and ease of manufacturing. There…
Local NBC affiliate NBC5 came to visit Vernal Bioscience to discuss the eventual move to a new, larger facility in Essex and our plans to nearly quadruple our workforce. Watch the story on NBC5.
Vernal produces high-purity mRNA to supply to companies that develop mRNA-based health treatments. Read the full story at VTDigger.
Vernal Biosciences has received $21 million from investors and is expanding to a new laboratory in Essex next year.
Vernal Biosciences has raised $21 million to build a manufacturing facility in Essex that will scale up the business from supporting research to being involved in clinical trials.
Vernal Biosciences announced today the completion of a $21 million financing to fully integrate its mRNA manufacturing solutions.
Vernal Biosciences has been awarded a $99,475 grant from the Vermont Training Program (VTP).
Vernal Biosciences, the Colchester-based manufacturer of mRNA used in cutting-edge medicines, plans to nearly triple the size of its staff, from 12 to 35, using a grant from the Vermont Training Program. Read the full story here.
Vernal Biosciences in Colchester helps make mRNA, which acts as a kind of roadmap a cell uses to make a specific protein.
Vernal Biosciences, a startup based in Colchester, is manufacturing mRNA for a range of pharmaceutical companies doing more than making vaccines. Read the full story here.
Christian Cobaugh, CEO of Vernal Biosciences in Colchester, explains how his company makes DNA and why it’s important for making mRNA. Read the full story here.
Five years ago, when Christian Cobaugh had the idea of starting a biotech company to manufacture mRNA, the genetic term wasn't in the vernacular of most nonscientists.